Last update 19 Sep 2024

NKG2D x CLDN18.2

Basic Info

Related Targets
NKG2DCLDN18.2

Related

1
Drugs associated with NKG2D x CLDN18.2
KD-496
Target
CLDN18.2 x NKG2D
Mechanism
CLDN18.2 inhibitors [+6]
Active Org.
Nanjing KAEDI Biotech, Inc.
Originator Org.
Nanjing KAEDI Biotech, Inc.
Active Indication
CLDN18.2 positive Solid Tumors [+3]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with NKG2D x CLDN18.2
NCT06134960
/ Not yet recruitingPhase 1IIT
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
NCT05583201
/ RecruitingEarly Phase 1IIT
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
100 Clinical Results associated with NKG2D x CLDN18.2
Login to view more data
100 Translational Medicine associated with NKG2D x CLDN18.2
Login to view more data
0 Patents (Medical) associated with NKG2D x CLDN18.2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free